FCS Weekly — Issue 2 · November 20, 2026
Qingyang · FCS Foundation Board Member & Tech Chair, FCS Foundation — and an FCS patient myself
A weekly digest for people living with familial chylomicronemia syndrome (FCS), their families, and caregivers.
This week's top stories
- EU approves Tryngolza for severe hypertriglyceridemia — the first RNA-targeted therapy authorized in the EU for adults with fasting triglycerides ≥880 mg/dL, widening the group of patients who can receive it.
- Plozasiran enters China's national reimbursement list — the first FCS drug covered by Chinese national insurance, effective January 1, 2027. For eligible adults in mainland China, treatment may become more affordable — but no negotiated price has been publicly disclosed yet.
- A head-to-head without a trial: a simulation model comparing plozasiran and olezarsen in FCS favors plozasiran — but the two drugs were never compared in the same trial, so this cannot prove one works better than the other in real patients.
What this means for patients this week
- In Europe, more adults with severe high triglycerides can now receive Tryngolza. The EU approval covers fasting triglycerides of 880 mg/dL and above — a higher bar than the FDA's 500 mg/dL in the US, so who qualifies still depends on where you live.
- In China, the first FCS drug is entering national insurance. From January 1, 2027, eligible adults should pay less — but the final reimbursed price has not been published, and being listed does not yet mean the drug is on pharmacy shelves at that price. Children with FCS are not covered by this listing.
- The plozasiran-versus-olezarsen comparison is interesting science, not a treatment guide. No one should switch drugs or choose between the two on the basis of a computer model. That decision stays between you and your doctor.
Research & new treatments
A model comparison of plozasiran vs. olezarsen in FCS (J Comp Eff Res, Nov 18)
No head-to-head trial of the two APOC3 drugs exists, so researchers built a microsimulation model — a computer model that simulates treatment in a virtual group of patients — using data from the two large FCS trials that tested each drug before approval: PALISADE (plozasiran) and BALANCE (olezarsen). Both drugs are RNA-targeted therapies: they work by blocking the genetic instructions for making APOC3, a protein that slows the clearing of triglycerides from the blood. In the model's main scenario, 56.8% of simulated patients on plozasiran reached triglycerides below 500 mg/dL at 10 months, versus 18.2% on olezarsen. The pattern held across the other scenarios the researchers tested and at every time point. Two things matter for reading these numbers. First, 56.8% and 18.2% are the model's predictions of how many simulated patients would reach the target — not success rates observed in a real trial. Second, a level below 500 mg/dL matters because pancreatitis risk rises sharply at very high triglycerides — but reaching it does not mean FCS is cured, or that pancreatitis risk is gone. The authors' own caution matters here: because the drugs were never compared directly in the same trial, this is an early indication from modeling, not proof that one drug works better than the other in real patients. The paper is by researchers at Yale School of Medicine and ADVI Health. A second indirect comparison, published in July, did the same kind of exercise for a different pair: using a matching-adjusted indirect comparison — a statistical method that reweights one trial's patients to resemble the other trial's population — researchers compared olezarsen with volanesorsen, the earlier APOC3 drug, injected once a week. At one year, there was no statistically significant difference in triglyceride lowering or pancreatitis. The numbers leaned toward olezarsen, but both trials were small (45 and 66 patients), so the study could not tell the drugs apart. Several of its authors work for Ionis and Sobi, the companies behind these drugs.
Patient takeaway: this study cannot tell you which drug is right for you, and it should not change any treatment decision — that choice is made with your doctor.
A new review: treating severe hypertriglyceridemia in a new era (JCEM, Nov 18)
A review in The Journal of Clinical Endocrinology & Metabolism surveys the new generation of triglyceride-lowering approaches — drugs that inhibit APOC3, ANGPTL3 (another protein that affects how the body clears fats from the blood) and other targets identified from human genetics — and where each stands in clinical development. Why does human genetics matter for finding new drugs? By studying how people's genes relate to their blood fat levels, researchers found new targets that drugs can now aim at. The review's bottom line: severe hypertriglyceridemia remains a major unmet need, and most of these emerging therapies are still limited to selected patient groups while broader uses are tested. Open access.
Eyes can flag severe chylomicronemia (J Clin Lipidol, Nov 11)
A narrative review — a summary and analysis of earlier studies — of eye findings in lipid disorders notes that lipemia retinalis — a milky appearance of the blood vessels at the back of the eye — indicates severe chylomicronemia (very high levels of chylomicrons, the particles that carry fat in the blood) and should prompt an assessment of pancreatitis risk. Other clues include xanthelasma (yellowish cholesterol deposits on the eyelids) and premature corneal arcus (a pale ring around the edge of the cornea, the clear front of the eye). But these last two need care in reading: they can appear in many people with abnormal lipids, they are not specific signs of FCS, and they cannot diagnose anything on their own. In someone with very high triglycerides, though, they can be a visible warning sign worth mentioning to a doctor. They cannot replace a blood test or a professional diagnosis — don't try to judge your own triglyceride level by looking in the mirror.
Recently published — not this week's news
- RNA-based lipid-lowering therapies, compared by target (Eur J Pharmacol, published online Oct 12, 2026; issue date Dec 10, 2026): a systematic review and meta-analysis of 16 randomized trials (5,604 participants) of inclisiran, olezarsen, plozasiran and zodasiran. APOC3-targeting therapies produced the greatest triglyceride reduction (mean −52.26%), while PCSK9-targeting therapy led on LDL cholesterol. Of the four drugs studied, only olezarsen and plozasiran are relevant to FCS. Overall safety looked comparable to placebo, but the authors note the lack of long-term clinical outcome data.
- Smoking and recurrence after hypertriglyceridemia-induced pancreatitis (Pancreatology, Nov 2026): in a multicenter cohort of 311 patients after a first episode of pancreatitis caused by high triglycerides — not an FCS-specific group — baseline current smoking was associated with a threefold higher hazard of a first recurrence (HR 3.00, meaning roughly three times the risk at any given time, compared with people who did not smoke) and a greater recurrence burden; the association was stronger after the first six months. Alcohol use was not independently associated with recurrence in this study.
Patient takeaway: quitting smoking may help lower the risk of another pancreatitis episode — but this study does not show that smoking causes every recurrence.
- Evinacumab, an ANGPTL3 antibody, in dyslipidemia (J Clin Lipidol, Oct 26, 2026): a systematic review of 9 randomized trials found LDL cholesterol reductions of roughly 16–50%, with triglyceride lowering particularly pronounced in severe hypertriglyceridemia, and a generally favorable safety profile. Note: evinacumab is approved for homozygous familial hypercholesterolemia, not for severe hypertriglyceridemia or FCS — this is evidence about the ANGPTL3 pathway, not a treatment option for FCS today.
Regulation & access
- EU: Tryngolza approved for severe hypertriglyceridemia (European Commission, Nov 17; Ionis and Sobi press releases): Tryngolza (olezarsen) is approved as an adjunct to diet, in combination with other lipid-lowering therapies, for adults with fasting triglycerides ≥880 mg/dL (≥10 mmol/L). It is the first and only RNA-targeted therapy authorized in the EU for that group, expanding the existing authorization for familial chylomicronemia syndrome. The decision is based on the Phase 3 CORE and CORE2 trials (617 and 446 patients) — Phase 3 means the large trials that test a drug's safety and effectiveness before approval — in which Tryngolza cut triglycerides by up to 73% at six months versus placebo and reduced the rate of acute pancreatitis events by 83% (company-reported). To read those two numbers clearly: 73% is the reduction in triglyceride levels, 83% is the relative reduction in the rate of pancreatitis events — a relative change, not 83 fewer cases out of every 100. Sobi will commercialize the drug in the EU. Context: the EMA's committee gave a positive opinion on October 16 (covered in Issue 1); this is the final decision. Note the threshold difference: in the US, the FDA approved Tryngolza for severe hypertriglyceridemia at ≥500 mg/dL in June 2026, a lower bar than the EU's ≥880 mg/dL.
Patient takeaway: the approval widens who can receive Tryngolza in Europe — but eligibility still depends on where you live, because the EU and US set different triglyceride thresholds.
- China: plozasiran (Redemplo) enters the 2026 national reimbursement list (National Healthcare Security Administration, Nov 14; confirmed by Sanofi the same day; first flagged to the patient community by the patient group 红米粒互助之家 on Nov 13): the 2026 National Reimbursement Drug List takes effect on January 1, 2027. It adds 107 drugs, 51 of them class-1 innovative drugs. For readers outside China: the list is China's national insurance formulary — drugs on it can be reimbursed under public insurance, which usually makes them much more affordable for patients. Plozasiran is the only drug approved in China to lower triglycerides in adults with FCS on top of diet (approved January 2026), given as a 25 mg injection under the skin every three months. Sanofi says its Phase 3 FCS study showed fasting triglycerides down about 86% at 10 months and pancreatitis recurrence risk down 83% (company statement — these are FCS figures, distinct from the SHASTA severe-hypertriglyceridemia figures in Issue 1). This is a Chinese reimbursement decision; it does not change Redemplo's pricing or coverage in the US or Europe. Two gaps to watch: no negotiated (reimbursement) price for the drug has been publicly disclosed — checked again on November 18 — and children with FCS are not covered by this listing. And one more distinction worth keeping in mind: approval, listing, a published reimbursement price, and actual hospital supply are separate steps — being listed does not yet mean patients can buy the drug at the final reimbursed price.
Patient takeaway: for eligible adults in mainland China, treatment may become more affordable from January 1, 2027 — but the final price is still unknown, and the listing alone does not mean the drug is available at that price yet.
Industry
- Arrowhead fiscal 2026: REDEMPLO's first year, and an sHTG filing is in (company earnings, Nov 12): REDEMPLO brought in $6.6 million in net product revenue in fiscal 2026 (ended September 30) — its first year of commercial sales for FCS. Arrowhead has applied to the FDA to add severe hypertriglyceridemia as a new use for plozasiran — a supplemental application, meaning an application to add a new use for an already approved drug — and entered the FDA's STAR pilot program, a pilot that can speed up review, for a six-month priority review. The company is preparing for a potential US launch in that indication in the second quarter of 2027, subject to approval. For patients, the practical read: the FCS launch is small but growing; the bigger test is the sHTG decision expected next year, which could widen who can receive the drug. The company puts the long-term US market for severe hypertriglyceridemia at $3–4 billion a year.
Patient resource
- A new patient guide: hypertriglyceridemia & acute pancreatitis (National Pancreas Foundation, Pancreas Press, November 2026): a free two-page handout explaining triglyceride levels, warning signs of pancreatitis, the tests to expect, hospital care, and long-term management — including a section on genetic causes such as FCS. It is a good starting point for people who are newly diagnosed and their families. One caution when reading it: the guide's very-low-fat diet figure (about 20–30 g of fat a day) is written for severe hypertriglyceridemia generally; people with FCS usually need less, around 10–20 g a day — but that is a common target, not a prescription for everyone, so follow the eating plan your own medical team and dietitian set for you. The guide is written for severe hypertriglyceridemia generally, not FCS specifically. The content was sponsored by Arrowhead Pharmaceuticals and Ionis Pharmaceuticals, both of which make APOC3 drugs.
Join us
Living with FCS or caring for someone who is? Join the FCS Support Group on Facebook: facebook.com/groups/livingwithfcs — patients, families and caregivers sharing practical experience. Families still learning about FCS are welcome too. The group shares practical experience; it is not a substitute for medical advice.
Sources
- Ionis Pharmaceuticals. TRYNGOLZA™ (olezarsen) approved in the EU for severe hypertriglyceridemia (sHTG) (press release, Nov 17, 2026). https://www.businesswire.com/news/home/20261116620597/en/TRYNGOLZA-olezarsen-approved-in-the-EU-for-severe-hypertriglyceridemia-sHTG
- Sobi. Tryngolza™ (olezarsen) approved in the EU for severe hypertriglyceridaemia (sHTG) (press release, Nov 17, 2026). https://www.prnewswire.com/news-releases/tryngolza-olezarsen-approved-in-the-eu-for-severe-hypertriglyceridaemia-shtg-302941809.html
- National Healthcare Security Administration (China). Notice on the 2026 National Basic Medical Insurance, Maternity Insurance and Work Injury Insurance Drug List (Nov 14, 2026). https://www.nhsa.gov.cn/art/2026/11/14/art_14_23385.html
- Sanofi. Two cardiovascular class-1 innovative drugs, including REDEMPLO (plozasiran), included in the new National Reimbursement Drug List (press release, Nov 14, 2026). https://www.prnasia.com/story/556396-1.shtml
- 红米粒互助之家 (Hongmili Mutual Aid Home). FCS 新药进医保了!(WeChat article, Nov 13, 2026). https://mp.weixin.qq.com/s/u-gyXAObvmR57C5VYNQW9Q
- Desai NR et al. Translating clinical trial efficacy data into population-level impact: a microsimulation model to compare APOC3 RNA inhibition on lowering triglycerides. J Comp Eff Res. 2026 Nov 18 (online ahead of print). https://pubmed.ncbi.nlm.nih.gov/43048772/
- Soran H et al. Comparative efficacy and safety of olezarsen versus volanesorsen for familial chylomicronemia syndrome: a matching-adjusted indirect comparison. J Comp Eff Res. 2026 Jul;15(7):e260069. https://pubmed.ncbi.nlm.nih.gov/42319369/
- Treatment of severe hypertriglyceridemia: a new era dawns. J Clin Endocrinol Metab. 2026 Nov 18 (open access). https://pubmed.ncbi.nlm.nih.gov/42497031/
- Ocular manifestations of lipid disorders: Clinical clues for lipidologists. J Clin Lipidol. 2026 Nov 11. https://pubmed.ncbi.nlm.nih.gov/43034116/
- Effectiveness and safety of target-specific RNA-based lipid-lowering therapies: A systematic review and meta-analysis of randomized controlled trials. Eur J Pharmacol. 2026 Dec 10 (issue date); published online Oct 12, 2026. https://pubmed.ncbi.nlm.nih.gov/42863556/
- Baseline current smoking and time-varying recurrence risk after first-episode of hypertriglyceridemia-induced acute pancreatitis: A multicenter retrospective cohort study. Pancreatology. 2026 Nov. https://pubmed.ncbi.nlm.nih.gov/42570923/
- The effect of evinacumab on the clinical outcomes of dyslipidemia: A systematic review of randomized controlled trials. J Clin Lipidol. 2026 Oct 26. https://pubmed.ncbi.nlm.nih.gov/42995029/
- Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals Reports 2026 Fiscal Year-End Results (Nov 12, 2026); earnings call transcript. https://www.fool.com/earnings/call-transcripts/2026/11/13/arrowhead-arwr-q4-2026-earnings-call-transcript/
- National Pancreas Foundation. A Patient's Guide: Hypertriglyceridemia & Acute Pancreatitis (Pancreas Press, November 2026). https://cdn.prod.website-files.com/6a69f75734891d656f7d3a99/6aeb7ef4018bc0cc0557db14_NPF%20sHTG%20Patient%20Handout.pdf
Company press releases are marked as such; their figures have not been peer-reviewed. This digest summarizes published research and company announcements for information only. It is not medical advice — talk to your doctor before making any change to your treatment or diet.
FCS Weekly is an independent project by Qingyang Li. The views and content are his own and do not represent the official position of The FCS Foundation or any other organization.
Support this digest
FCS Weekly is a one-person project. If it helped you, consider buying me a coffee — it keeps the research going.
